1) 日本肝臓学会, 編. B型肝炎治療ガイドライン (第3.4版). 2021. https://www.jsh.or.jp/lib/files/medical/guidelines/jsh_guidlines/B_v3.4.pdf
2) Hosaka T, Suzuki F, Kobayashi M, et al. Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection. Hepatology. 2013 ; 58 : 98-107.
3) Suzuki F, Hosaka T, Suzuki Y, et al. Long-term outcome of entecavir treatment of nucleos (t) ide analogue-naive chronic hepatitis B patients in Japan. J Gastroenterol. 2019 ; 54 : 182-93.
4) Kitrinos KM, Corsa A, Liu Y, et al. No detectable resistance to tenofovir disoproxil fumarate after 6 years of therapy in patients with chronic hepatitis B. Hepatology. 2014 ; 59 : 434-42.
5) Koike K, Suyama K, Ito H, et al. Randomized prospective study showing the non-inferiority of tenofovir to entecavir in treatment-naive chronic hepatitis B patients. Hepatol Research. 2018 ; 48 : 59-68.
6) Suzuki F,Suzuki Y,Hosaka T, et al. Efficacy of long-term tenofovir-based rescue therapy in patients with chronic hepatitis B refractory to nucleoside/nucleotide analogs. J Gastroenterol. 2017 ; 52 : 641-51.
7) Suzuki F, Sezaki H, Hosaka T,et al. Virologic analysis of tenofovir resistance in a patient with chronic hepatitis B experiencing viral breakthrough during combination treatment with tenofovir disoproxil fumarate and entecavir. Hepatol Res. 2021 ; 51 : 503-8.
8) Agarwal K, Brunetto M, Seto WK, et al. 96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection. J Hepatol. 2018 ; 68 : 672-81.
9) Hagiwara S, Nishida N, Ida H, et al. Switching from entecavir to tenofovir alafenamide versus maintaining entecavir for chronic hepatitis B. J Med Virol. 2019 ; 91 : 1804-10.
10) Itokawa N, Atsukawa M, Tsubota A, et al. Sequential therapy from entecavir to tenofovir alafenamide versus continuous entecavir monotherapy for patients with chronic hepatitis B. JGH Open. 2020 ; 5 : 34-40.
11) Uchida Y, Nakao M, Tsuji S, et al. Significance of switching of the nucleos (t) ide analog used to treat Japanese patients with chronic hepatitis B virus infection from entecavir to tenofovir alafenamide fumarate. J Med Virol. 2020 ; 92 : 329-38.
12) Ogawa E, Nomura H, Nakamuta M, et al. Tenofovir alafenamide after switching from entecavir or nucleos (t) ide combination therapy for patients with chronic hepatitis B. Liver Int. 2020 ; 40 : 1578-89.
13) Nguyen MH, Atsukawa M, Ishikawa T, et al. Outcomes of sequential therapy with tenofovir alafenamide after long-term entecavir. Am J Gastroenterol. 2021 ; 116 : 1264-73.
14) Byun KS, Choi J, Kim JH, et al. Tenofovir alafenamide for drug-resistant hepatitis B : A randomized trial for switching from tenofovir disoproxil fumarate. Clin Gastroenterol Hepatol. 2021 ; 20 : 427-37. e5.
15) Sano T, Amano K, Ide T, et al. Short-term efficacy after switching from adefovir dipivoxil and tenofovir disoproxil fumarate therapy to tenofovir alaferamide for chronic hepatitis B. Biomed Rep. 2021 ; 14 : 12.
16) Yamashige D, Hosaka T, Suzuki F, et al. Effectiveness of tenofovir alafenamide for chronic hepatitis B patients with a poor response to the previously used nucleos (t) ide analogs. J Gastroenterol. 2021 ; 56 : 1008-21.
17) Brouwer WP, Xie Q, Sonneveld MJ, et al. Adding pegylated interferon to entecavir for hepatitis B e antigenpositive chronic hepatitis B : A multicenter randomized trial (ARES study). Hepatology. 2015 ; 61 : 1512-22.
18) Matsumoto A, Nishiguchi S, Enomoto H, et al. Combinational use of hepatitis B viral antigens predicts responses to nucleos (t) ide analogue/peg-interferon sequential therapy. J Gastroenterol. 2018 ; 53 : 247-57.